Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — LD Micro (Zooming with LD Micro) (July 2021)
14 slides from Processa Pharmaceuticals's conference presentation, Jul 30, 2021
Slide 1: Processa Pharmaceuticals: Zooming with LD Micro
@ Processa Pharmaceuticals Zooming with LD Micro July 29, 2021 David Young, PharmD, PhD Chairman and CEO
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer: Forward Looking Statements The following summary is provided for informational purposes only and does not constitute an offer or solicitation to acquire interests in the investment or any related or associated company. The information contained here is general in nature and is not intend
Slide 3: Processa Highlights
Processa Highlights Increase Prob. of Approval + Experienced Exec. Team & Staff +- Drug Development Regulatory Science Platform +- Pipeline Drugs Selected to Increase Prob of Success & Mitigate Risk *Regulatory Science Appproach +30 FDA Approvals, 100 FDA Meetings, 2 FDA Regulatory Science Contracts
Slide 4: Processa Capital Structure and Share Information
Processa Capital Structure and Share Information on March 31, 2021 > Stock Listing: PCSA-NASDAQ > 52 Week Low-High: $3.95 - $13.15 > Price (July 23, 2021): $7.00 > Market Cap (July 23, 2021): $108,651,312 > Shares Outstanding: 15,521,616 > Fully Diluted Shares: 16,511,147 > Cash, Cash Equivalents: $
Slide 5: Processa's Risk Abated Approach and Criteria for Drug Selection
Processa’s Risk Abated Approach and Criteria for Drug Selection Experience in Adding Value to Companies: > 30 FDA Approvals & Regulatory Science Contracts from FDA DEVELOP NOT DISCOVER * Clear and obvious patient need ° Favorable competitive dynamics @ Processa Pharmaceuticals Unmet Medical Need + o
Slide 6: Processa Pipeline - Multiple Opportunities For Success
Processa Pipeline - Multiple Opportunities For Success Pipeline of Drugs with Funding to Obtain Results for Key Milestones Drug Disease Target Preclinical Phase 1 Phase 2 Phase 3 Milestones Pcs499 Ulcerative Interim Analysis 1H’22; Phase 2B Necrobiosis ee) * Final Analysis 2H’22; Lipoidica FPI Phase
Slide 7: PCS499 to Be First to Market for the Treatment of Ulcerative Necrobiosis Lipoidica (uNL)
PCS499 to Be First to Market for the Treatment of Ulcerative Necrobiosis Lipoidica (uNL) Severe NL Skin, tissue below the skin becomes necrotic, last from months to years with complications such as infections, amputation; Histopathology = diabetic ulcers 30% of NL patients have painful ulcers occurr
Slide 8: Unmet Medical Need, Evidence of Clinical Efficacy, PCS499 Improves Benefit-Risk
a Unmet Medical Need, Evidence of Clinical Efficacy, PCS499 Improves Benefit-Risk > PCS499 is the deuterated analog of a major metabolite of PTX; has identical metabolites and pharmacological targets but PK of 499 + metabolites is different than PTX + metabolites resulting in a better 499 safety pro
Slide 9: PCS3117 to Treat Gemcitabine Resistant Pancreatic and Lung Cancer Patients
a PCS3117 to Treat Gemcitabine Resistant Pancreatic and Lung Cancer Patients » Gemcitabine is the most widely used chemotherapeutic agent used to treat pancreatic and non- small cell lung cancer > 55% - 85% of patients are inherently resistant to gemcitabine or acquire resistance; inherent or acquir
Slide 10: Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine
Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine > Biomarker assays are being developed and evaluated to potentially define a targeted, personalized medicine approach to identifying patients who will respond to 3117 better than gemcitabine > Patients more likely to r
Slide 11: PCS6422 Combined with Capecitabine To Provide Better Safety/Efficacy Profile
PCS6422 Combined with Capecitabine To Provide Better Safety/Efficacy Profile PCS6422 Irreversibly Inhibits Dihydropyrimidine Dehydrogenase (DPD) Enzyme Capecitabine 6422 Inhibits DPD Allowing Two Ways to Win (Xeloda®) > Lower Side Effects by Lowering 5-FU Metabolite FBAL- Potentially Improve QOL & R
Slide 12: Unmet Medical Need and Evidence of Clinical Benefit
Unmet Medical Need and Evidence of Clinical Benefit > Safety Differentiation of 6422 + Capecitabine vs Existing Chemotherapy Dédiease Incidence of HES (Grade 3&4) FBAL Side Effects 10 + 50-70% of capecitabine patients have adverse events from FBAL 2 resulting in decreasing capecitabine dose or stopp
Slide 13: Processa Pipeline - Multiple Opportunities For Success
Processa Pipeline - Multiple Opportunities For Success Pipeline of Drugs with Funding to Obtain Results for Key Milestones Drug Disease Target Preclinical Phase 1 Phase 2 Phase 3 Milestones Pcs499 Ulcerative Interim Analysis 1H’22; Phase 2B Necrobiosis ee) * Final Analysis 2H’22; Lipoidica FPI Phase
Slide 14: Our People Lead to Success
Our People Lead to Success Management Team David Young, PharmD. PhD Sian Bigora, PharmD. Michael Floyd Chief Executive Officer, Chairman of the Board Chief Development Officer Chief Operating Officer Patrick Lin James Stanker, CPA Wendy Guy Chief Business — Strategy Officer Chief Financial Officer C
Processa Pharmaceuticals — LD Micro (Zooming with LD Micro) (July 2021) on 6ix